AIM ImmunoTech

Veja o organograma con seus 8 executivos principais

Biografias mais buscadas da AIM ImmunoTech

• Thomas Equels, Executive Vice Chairman, Chief Executive Officer an...
• Nancy Bryan, Director
• William Mitchell, Chairman of the Board

Criar um alerta
para seguir os movimentos de executivos da AIM ImmunoTech.

AIM ImmunoTech possui 2.277 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Adaptive Phage Therapeutics (Estados Unidos).

Popular M&A news in Biotecnologia

• Histogen has filed for bankruptcy protection  (publicado em 19 de abril de 2024).
• Bruker has announced the acquisition of NanoString Technologies  (publicado em 18 de abril de 2024).
• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (publicado em 16 de abril de 2024).

Outros contatos sugeridos na indústria do Biotecnologia

• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics
• Vik Bajaj - Director da Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board da Sensorion

Saiba mais sobre a indústria do Biotecnologia >

Últimos comunicados de imprensa de AIM ImmunoTech

• Press Releases | AIM Immunotech
• AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise - AIM ImmunoTech Inc.
• AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast - AIM ImmunoTech Inc.
• AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease - AIM ImmunoTech Inc.
• AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease - AIM ImmunoTech Inc.
• AIM ImmunoTech Issues Letter to Stockholders - AIM ImmunoTech Inc.
• AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients - AIM ImmunoTech Inc.
• AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, "Long Covid: What Will It Take To Accelerate Therapeutic Progress?" - AIM ImmunoTech Inc.
• AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center - AIM ImmunoTech Inc.
• AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention - AIM ImmunoTech Inc.
• View more press releases Close

Redes sociais sobre AIM ImmunoTech

• AIM ImmunoTech na Wikipedia, Google News e Yahoo Finance
• AIM ImmunoTech na LinkedIn, Twitter e YouTube

Contate seus executivos por e-mail agora, incluindo Thomas Equels

Ligue para a AIM ImmunoTech em +1 212...

Veja o organograma

Register to receive your alert

Relatório um erro